Scientists Cut a Cholesterol Gene Once. The Effect Lasted a Year. Could It Last a Lifetime?

A first-in-human CRISPR study kept LDL cholesterol and triglycerides about 50 percent lower at the highest dose after 12 months. The biological signal is remarkable, but the evidence is still far too small to call it a cure.

By Karla Alvarado Follow

Published at 10:01 p.m. EDT

For generations, doctors have treated dangerously high cholesterol as a chronic problem requiring chronic management. Patients change how they eat, exercise more, take a statin every day, add another pill when that is not enough, or receive an injection every few weeks or months. The medicines can be highly effective, but their benefit depends on access, tolerance and the unglamorous discipline of continuing treatment for years.

Scientists are now testing a fundamentally different proposition: alter a gene in the liver once and keep harmful blood fats lower long after the infusion is over.

New one-year data reported on August 28 have brought that possibility closer to medicine, though not yet close enough for ordinary clinical use. In a 15-person Phase 1 trial, an experimental CRISPR-Cas9 treatment called CTX310 switched off a liver gene known as ANGPTL3. Among the four participants who received the highest dose, LDL cholesterol was an average of 52.5 percent below baseline after 12 months. Triglycerides were down 47.8 percent, while circulating ANGPTL3 protein was down 78.6 percent.

The results were presented at the European Society of Cardiology Congress and published in a New England Journal of Medicine follow-up report. Cleveland Clinic, whose researchers helped lead the study, described the lasting lipid reduction in an August 28 summary.

The central finding is real and important. The treatment’s effect did not vanish after a few weeks. Yet the phrase “for life” remains a scientific aspiration, not a demonstrated outcome. Twelve months is meaningful durability. It is not a lifetime. Four people at the highest dose are a signal, not a verdict.

The target came from a natural experiment

The idea behind CTX310 begins with people who were effectively born into the experiment.

ANGPTL3 is a gene that directs the production of a liver protein involved in regulating how the body handles triglycerides and cholesterol. Researchers have observed that people with naturally occurring loss-of-function variants in ANGPTL3 tend to have unusually low levels of LDL cholesterol and triglycerides. They also appear to have a lower lifetime risk of atherosclerotic cardiovascular disease without an obvious pattern of serious harm from the missing protein.

That genetic evidence gave scientists a target. Instead of repeatedly blocking the ANGPTL3 protein with medicine, CTX310 is designed to disrupt the instructions for making it inside liver cells.

The treatment packages two biological components inside microscopic lipid particles: messenger RNA that tells a cell to produce the Cas9 cutting enzyme and a guide RNA programmed to find a specific sequence in ANGPTL3. After an intravenous infusion, the particles travel primarily to the liver. The guide directs Cas9 to the intended DNA site, where it makes a cut. The cell’s own repair process then introduces a change that disables the gene.

This is somatic editing. It is aimed at cells in the treated person’s liver, not eggs or sperm, and the edit is not designed to be inherited by future children. The intervention is nevertheless intended to be durable. Unlike a pill that can be stopped or an injection that eventually wears off, the altered DNA cannot simply be recalled if an unforeseen problem emerges.

That permanence is both the attraction and the risk.

What the trial actually showed

The Phase 1a trial enrolled 15 adults with uncontrolled high cholesterol, high triglycerides or mixed lipid disorders despite maximally tolerated treatment. Participants received one intravenous dose ranging from 0.1 to 0.8 milligrams per kilogram of lean body weight. Most were already taking statins, ezetimibe or both, and 40 percent were using PCSK9 inhibitors, according to the sponsor’s trial update.

This was an open-label, dose-escalation safety study. There was no placebo group. Participants had different lipid disorders, and the doses varied. Thirteen of the 15 participants were men, and 14 were White, according to a trial summary from the American College of Cardiology. Those features sharply limit how confidently the findings can be extended to women, more diverse populations or the millions of people with routine high cholesterol.

The most publicized result came from the four people at the top dose. That is 26.7 percent of the entire study, based on this reporter’s calculation. At one year, their LDL responses also varied substantially, ranging from a 24.4 percent reduction to an 84.2 percent reduction. The average reduction of 52.5 percent is impressive, but it compresses a wide range of individual outcomes.

The same four-person group had an average triglyceride reduction of 47.8 percent, with individual changes ranging from a 14.7 percent reduction to a 77.6 percent reduction. ANGPTL3 fell by an average of 78.6 percent. The persistence across all three markers strengthens the biological case that the edit remained active.

What the trial did not test was whether CTX310 prevented heart attacks, strokes, procedures or deaths. It was too small and too short for those questions. Its primary purpose was to assess safety and tolerability. Changes in ANGPTL3 and blood lipids were secondary measures.

That difference matters. A lower laboratory number can be encouraging without yet proving that patients live longer or avoid cardiovascular emergencies.

The safety story requires the full record

The latest update reported no dose-limiting toxicities, no treatment-related serious adverse events and no new treatment-related events during extended follow-up. Three participants experienced moderate infusion reactions that resolved, and one participant had an allergic reaction that resolved with supportive care. Another participant, who already had elevated liver enzymes, experienced a temporary further increase that peaked four days after treatment and returned to baseline by day 14.

There is an additional fact that shorter accounts can miss. The original peer-reviewed Phase 1 report indexed by the National Library of Medicine recorded two serious adverse events. One participant developed a spinal disk herniation. Another, a person with extensive cardiovascular disease who received the lowest dose, died suddenly 179 days after treatment. Investigators judged both events unrelated to CTX310.

That assessment is important, but so is the underlying record. Saying there were no treatment-related serious events is not the same as saying no serious events occurred. Transparent reporting requires both statements.

The study was funded by CRISPR Therapeutics. Cleveland Clinic says Luke Laffin’s institution received research funding from the company. Those disclosures do not invalidate the findings, but they help readers understand the financial relationship around the research.

The participants are expected to undergo long-term safety monitoring. The Food and Drug Administration recommends up to 15 years of follow-up for genome-editing products because delayed risks may take years to surface.

In April 2026, the FDA also issued draft guidance on sequencing-based safety assessment. It specifically highlights off-target editing and unintended changes to genome integrity as risks that development programs should investigate.

Those concerns are not abstract. A gene editor must reach enough of the intended liver cells to work, cut the intended DNA sequence accurately, avoid harmful changes elsewhere, and avoid provoking unacceptable immune or liver reactions. It must do all of that in a treatment whose central promise is that the effect will not wear off.

A second program strengthens the signal

CTX310 is not the only attempt to build a one-time cholesterol treatment.

Eli Lilly is developing VERVE-102, an experimental base-editing therapy aimed at PCSK9, another liver gene with powerful effects on LDL cholesterol. PCSK9 normally reduces the liver’s ability to clear LDL from the blood. People born with variants that disable the gene can have very low LDL throughout life and strong protection against coronary disease.

VERVE-102 uses a base editor, which changes a DNA letter without relying on the same type of double-strand cut used by conventional CRISPR-Cas9. In May, Lilly reported interim results from 35 participants with heterozygous familial hypercholesterolemia or premature coronary artery disease. At the highest tested dose, mean PCSK9 fell 88 percent and mean LDL fell 62 percent. A subset had been followed for as long as 18 months.

Lilly reported no treatment-related serious adverse events or dose-limiting toxicities in that interim analysis, although low-grade infusion reactions and fatigue occurred. The company said the FDA had granted VERVE-102 Fast Track designation and that it planned to begin a Phase 2 study by the end of 2026. The detailed numbers and trial limitations are available in Lilly’s May 25 report.

The VERVE program also offers a warning about how quickly the field can change. Enrollment in a predecessor study of VERVE-101 was paused in 2024 after a participant developed elevated liver enzymes and abnormally low platelets, Reuters reported. The newer treatment uses a modified delivery strategy, but that history illustrates why early safety success cannot be treated as permanent reassurance.

Two different gene targets, two editing systems and two small human programs now point in the same broad direction: a single liver-directed infusion can produce substantial LDL lowering that lasts at least a year in some high-risk patients. That convergence is more persuasive than either trial alone. It still does not establish lifelong safety or cardiovascular benefit.

“For life” is the hope, not the evidence

Researchers have good biological reasons to expect a long effect. Gene editing changes DNA rather than temporarily blocking a protein. When edited liver cells divide, descendant cells may retain the alteration. Animal studies and human genetic evidence add confidence that disabling ANGPTL3 or PCSK9 can produce durable lipid changes.

But scientists cannot compress decades of observation into 12 or 18 months. Liver cells turn over. Individual editing levels vary. Rare off-target changes might not become apparent in a 15-person study. An unexpected metabolic consequence could take years to detect. The risk calculation also changes when an irreversible treatment moves from patients facing exceptional cardiovascular danger to otherwise healthy people whose cholesterol can be controlled with established medicine.

In an interview published by the Associated Press in February, Laffin captured the appeal in seven words: “People want a fix, not a bandage.” The same AP report included cautions from Stanford cardiologist Joseph Wu about liver inflammation, unintended targets and the limited long-term experience with CRISPR therapies.

Both ideas can be true. Patients understandably want freedom from decades of medication, and permanent editing demands a higher standard of certainty precisely because it cannot be discontinued.

Today delivered a timely warning about biomarkers

On the day this article was filed, a separate cardiovascular program supplied a sobering comparison. Novartis said its experimental drug pelacarsen lowered lipoprotein(a), or Lp(a), but failed to reduce major heart attacks and strokes in a Phase 3 study of more than 8,000 patients that ran for over six years, according to Reuters.

Pelacarsen is not a gene-editing treatment, and Lp(a) is not LDL or ANGPTL3. Its failure does not predict that CTX310 or VERVE-102 will fail. The comparison should not be stretched beyond what the evidence allows.

It does reinforce a crucial rule of cardiovascular medicine: changing a biomarker is not the final objective. Preventing heart attacks, strokes, disability and death is the objective. Large, randomized outcome trials will eventually have to show whether permanent gene editing improves those outcomes enough to justify its irreversible risks.

Who would receive it first

If one of these therapies reaches the market, the first patients are unlikely to be people with mildly elevated cholesterol discovered during a routine physical.

The most defensible early candidates would be people with inherited or otherwise severe lipid disorders, established cardiovascular disease, persistently dangerous levels despite available therapy, or major difficulty tolerating or accessing existing treatment. For those patients, the danger of doing too little may outweigh uncertainties that would be unacceptable for a lower-risk person.

Cost and access will matter too. A one-time therapy could prevent years of pharmacy bills and adherence problems, but gene-editing treatments are complex to manufacture, administer and monitor. Pricing has not been announced for these investigational products. Insurers and health systems will eventually have to decide how to value a treatment whose expense arrives at once while its promised benefit stretches across decades.

There is also a basic issue of trust. Patients will need to understand what is being edited, where the edit is expected to occur, which risks are known, which remain theoretical, and what happens if the company that sponsors 15 years of monitoring is sold or leaves the program. Consent for a permanent intervention cannot become a glossy synonym for signing a form.

What patients should do now

CTX310 and VERVE-102 remain investigational. Neither is an approved replacement for statins or other cholesterol-lowering treatment. No one should stop prescribed medicine because of an early gene-editing result.

Current care still rests on measuring cardiovascular risk, improving diet and physical activity, avoiding tobacco, managing blood pressure and diabetes, and using proven lipid-lowering medication when indicated. The Centers for Disease Control and Prevention identifies high blood cholesterol as a key risk factor for heart disease, which remains the leading cause of death in the United States.

The scale of the problem explains the urgency. The American Heart Association reported that an estimated 86.4 million U.S. adults had total cholesterol of at least 200 milligrams per deciliter. Globally, the World Health Organization estimates that cardiovascular diseases caused 19.8 million deaths in 2022, with heart attacks and strokes responsible for most of them.

A safe one-time treatment that produces decades of LDL reduction could become one of the most consequential preventive tools in modern medicine. It could also expose healthy people to irreversible risk if enthusiasm moves faster than evidence.

The latest results deserve excitement disciplined by precision. Scientists have shown that they can edit a cholesterol-related gene inside the human body and keep the biological effect visible one year later. They have not shown that the benefit lasts for life. They have not shown that it prevents a single heart attack. They have not established safety across thousands of diverse patients.

The experiment has crossed an extraordinary threshold. The proof must now catch up with the promise.

Reporting and interview disclosure

This article was written and analyzed by Karla Alvarado using peer-reviewed research, regulator guidance, trial registries, medical-society summaries, institutional disclosures and current news reports. Karla Alvarado did not conduct a private or live interview for this article. The quoted remark from Dr. Luke Laffin came from an interview conducted and published by the Associated Press.

Original reporting in this article consists of cross-source verification, comparison of the two leading gene-editing programs, calculation of the highest-dose cohort’s share of the CTX310 trial, examination of the complete reported safety record, and analysis distinguishing biomarker durability from proven cardiovascular benefit.

Sources

Medical note: This article is general reporting, not personal medical advice. Readers should discuss cholesterol testing and treatment decisions with a licensed healthcare professional.